A previous study demonstrated that the loss of ATM did not impact the development of murine AML driven by MLL-AF9 in primary transplants; however, the inhibition of ATM significantly alleviated the disease burden and extended the survival of leukaemia mice [12]. The gene discussed is KMT2A; the disease is acute myeloid leukemia.